← Back to Search

Digital Therapeutic

HPDT-DA-013 for Generalized Anxiety Disorder

N/A
Waitlist Available
Led By Roger Vilardaga, Ph.D.
Research Sponsored by Happify Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, average of 14 months
Awards & highlights

Study Summary

This trial will test a digital therapeutic for people with Major Depressive Disorder or Generalized Anxiety Disorder.

Eligible Conditions
  • Depression
  • Generalized Anxiety Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, average of 14 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, average of 14 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Generalized Anxiety Disorder-7 (GAD-7)
Patient Health Questionnaire-9 (PHQ-9)
Secondary outcome measures
GAD-7
PHQ-9

Trial Design

1Treatment groups
Experimental Treatment
Group I: Digital therapeuticExperimental Treatment1 Intervention
Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HPDT-DA-013
2021
N/A
~370

Find a Location

Who is running the clinical trial?

Happify Inc.Lead Sponsor
6 Previous Clinical Trials
21,257 Total Patients Enrolled
Roger Vilardaga, Ph.D.Principal InvestigatorDuke University
~98 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top